Last reviewed · How we verify
RP followed by MPR — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
RP followed by MPR (RP followed by MPR) — Fondazione EMN Italy Onlus.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| RP followed by MPR TARGET | RP followed by MPR | Fondazione EMN Italy Onlus | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- RP followed by MPR CI watch — RSS
- RP followed by MPR CI watch — Atom
- RP followed by MPR CI watch — JSON
- RP followed by MPR alone — RSS
Cite this brief
Drug Landscape (2026). RP followed by MPR — Competitive Intelligence Brief. https://druglandscape.com/ci/rp-followed-by-mpr. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab